LifeCell and Tornier sign distribution agreement

The agreement provides for the two companies to collaborate on the development of certain orthopaedic soft tissue repair applications for which Tornier will distribute the product to its orthopaedic and podiatric surgeon customer base under the ‘Conexa’ private label brand. Currently, LifeCell markets and distributes the tissue matrix for general soft tissue repair applications under Strattice reconstructive tissue matrix.

LifeCell’s animal studies and early clinical investigation in general soft tissue repair applications have demonstrated that the new porcine-derived tissue matrix performs essentially equivalent to its flagship human tissue matrix, AlloDerm, demonstrating that it allows for tissue regeneration.

Doug Kohrs, president and CEO of Tornier, said: “We are very excited to have the opportunity to partner with LifeCell to extend the availability of its innovative porcine-derived tissue matrix technology to our surgeon customers. Our collaboration with LifeCell further evidences Tornier’s commitment to new biomaterials and biologic technologies to improve clinical outcomes for both soft and hard tissue repairs.”